A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone.

@article{Hartmaier2012ASI,
  title={A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone.},
  author={Ryan J. Hartmaier and Alexandra S Richter and Ryan Gillihan and Jad Sallit and Sean E. McGuire and Jian Wang and Adrian V. Lee and Charles Osborne and Bert W O'malley and Powel H. Brown and Jianming Xu and Todd C. Skaar and Sanosh Philips and James Michael Rae and Fayçal Azzouz and LePing Li and James Hayden and N Lynn Henry and Andrew T. Nguyen and Vered Stearns and Daniel F. Hayes and David A. Flockhart and Steffi Oesterreich},
  journal={Molecular endocrinology},
  year={2012},
  volume={26 2},
  pages={220-7}
}
The coregulator steroid receptor coactivator (SRC)-1 increases transcriptional activity of the estrogen receptor (ER) in a number of tissues including bone. Mice deficient in SRC-1 are osteopenic and display skeletal resistance to estrogen treatment. SRC-1 is also known to modulate effects of selective ER modulators like tamoxifen. We hypothesized that single nucleotide polymorphisms (SNP) in SRC-1 may impact estrogen and/or tamoxifen action. Because the only nonsynonymous SNP in SRC-1… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…